[The effect of fenazepam and sidnocarb in the phantom pain syndrome].
The phantom-pain syndrome model was used to examine the effects of phenazepam, sydnocarb and their combination in chronic oral administration. Phenazepam was shown to have no effects on the development of the phantom-pain syndrome. Sydnocarb arrested the progression of the pain syndrome, reduced its symptoms, alleviated inflammatory manifestations and extremity edema. The agent increased animals' excitability. When their combination was used, the clinical signs of the pain syndrome developed in the same way as with sydnocarb alone. At the same time phenazepam decreased the animals' aggression and excitability caused by sydnocarb. It is suggested that enhancing the efficiency of inhibitory GABAergic processes may result in lower clinical signs of the phantom-pain syndrome in case of involvement of brain catecholaminergic systems whose activation increases the inhibitory functions of its related GABA. The sympathomimetic action of sydnocarb induces an elevation of norepinephrine concentrations in the nerve endings and postsynaptic receptors, resulting in trophic improvement and restoration of tissue viability.
Danilova
E I
EI
Grafova
V N
VN
Reshetnik
V K
VK
D000818:Animals; D014151:Anti-Anxiety Agents / Q000627:therapeutic use*; D001569:Benzodiazepines; D001570:Benzodiazepinones / Q000627:therapeutic use*; D002908:Chronic Disease; D004195:Disease Models, Animal; D004353:Drug Evaluation, Preclinical; D004359:Drug Therapy, Combination; D008297:Male; D010146:Pain / Q000188:drug therapy*; D017288:Pain Threshold / Q000187:drug effects; D010591:Phantom Limb / Q000188:drug therapy*; D011619:Psychotropic Drugs / Q000627:therapeutic use*; D051381:Rats; D013558:Sydnones / Q000627:therapeutic use*; D013577:Syndrome
D014151:Anti-Anxiety Agents; D001570:Benzodiazepinones; D011619:Psychotropic Drugs; D013558:Sydnones; D001569:Benzodiazepines; C017928:phenazepam; C009257:sidnocarb
Effekty fenazepama i sidnokarba pri fantomno-bolevom sindrome.